🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Sirolimus in the Treatment of Refractory/Relapsed wAIHA

RecruitingNAAges 18 Years - 90 YearsAllPeking Union Medical College Hospital
NCT05925023 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

Autoimmune hemolytic anemia (AIHA) is a rare and heterogeneous disorder characterized by the destruction of red blood cells through warm or cold antibodies. Glucocorticoid (combined with rituximab) is the first-line treatment. However, the recurrence rate is very high and some patients may not respond to steroids. Second-line therapies include cyclosporine A (CsA), cyclophosphamide, rituximab, azathioprine, and even splenectomy. Our previous study of sirolimus in refractory/relapsed AIHA and ES found an effective rate of 80%. Therefore, the investigators plan to explore the efficacy and safety of sirolimus in the treatment of refractory/relapsed wAIHA.

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: 1. Age ≥18 years old. 2. Diagnosed as primary warm autoimmune hemolytic anemia or Evans syndrome (primary or secondary). There is no treatment indication of other systemic involvement in the original disease if secondary. 3. No response to glucocorticoid therapy or recurrence. 4. Baseline liver (ALT, AST) was less than 2 times the normal value. 5. No active infection; Not pregnant or breastfeeding. 6. Agree to sign the consent form. Exclusion Criteria: 1. Patients with connective tissue disease or other organs involvement 2. Infection or bleeding that cannot be controlled by standard treatment. 3. Active HIV, HCV or HBV infection or cirrhosis or portal hypertension. 4. Progressed uncontrolled malignant tumors and lymphoma 5. Cirrhosis or portal hypertension. 6. Pregnant or breastfeeding.
💊

What it tests

  • Sirolimus
📍

Where

1 site
Peking Union Medical College Hospital
Beijing, China
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy